KBY Biotech Indexv0.0.34
Search
← Pipeline|Lisotinib

Lisotinib

Approved
BIO-1067
By Biocon Biologics
Source: Trial-derived·Trials: 3
Modality
Fusion Protein
MOA
PD-1i
Target
SGLT2
Pathway
Cell Cycle
LN
Development Pipeline
Preclinical
~May 2010
→ ~Aug 2011
Phase 1
~Nov 2011
→ ~Feb 2013
Phase 2
~May 2013
→ ~Aug 2014
Phase 3
~Nov 2014
→ ~Feb 2016
NDA/BLA
~May 2016
→ ~Aug 2017
Approved
Nov 2017
→ Dec 2031
ApprovedCurrent
NCT06907737
2,731 pts·LN
2022-07→2031-12·Terminated
NCT04126807
1,624 pts·LN
2017-11→TBD·Terminated
NCT04845164
2,717 pts·LN
2025-12→TBD·Terminated
7,072 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-12-245.7y awayPh3 Readout· LN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Termina…
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2031-12-24 · 5.7y away
LN
Terminated|StartCompletionToday
Trials (3)
NCTPhaseIndicationStatusNEP
NCT06907737ApprovedLNTerminated2731Safety
NCT04126807ApprovedLNTerminated1624UPDRS
NCT04845164ApprovedLNTerminated2717ORR
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-7558RochePhase 1SGLT2Anti-Tau
TiramavacamtenRochePreclinicalSGLT2PI3Ki
RimatenlimabNovo NordiskPhase 2/3SGLT2PI3Ki
GSK-7987GSKPhase 3MDM2PD-1i
DSN-7360Daiichi SankyoApprovedSGLT2BiTE
NirabrutinibBioNTechPhase 2/3CDK2PD-1i
CevinaritideGenmabPhase 2/3DLL3PD-1i
SRP-3270SareptaPhase 1/2SGLT2PI3Ki
TirarapivirUnited TherapeuticsApprovedSGLT2CD47i
PexanaritideInnovent BioPreclinicalSGLT2USP1i